Movalis (Meloxicam)

Meloxicam, the active ingredient in Movalis, is a nonsteroidal anti‑inflammatory drug (NSAID) of the oxicam class presented as an oral tablet for oral use. It is prescribed to reduce inflammation and pain associated with chronic musculoskeletal conditions and acute pain episodes.

GNH USA supplies Movalis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Movalis (meloxicam) is used in the management of inflammatory joint disorders and acute pain.

- Osteoarthritis: alleviates joint pain and improves mobility. - Rheumatoid arthritis: reduces synovial inflammation and joint swelling. - Ankylosing spondylitis: diminishes spinal stiffness and pain. - Acute pain: provides rapid relief of moderate to severe pain episodes.

Adverse reactions to meloxicam may vary in frequency and severity.

Common Side Effects: - Gastrointestinal upset (nausea, dyspepsia) - Headache - Dizziness - Mild skin rash

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding - Cardiovascular events such as myocardial infarction - Hepatic injury (elevated transaminases) - Severe skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis)

When prescribing meloxicam, clinicians should consider several safety aspects.

- Renal function: monitor in patients with existing kidney disease. - Cardiovascular risk: assess history of heart disease or stroke. - Gastrointestinal health: avoid in patients with active ulcers or severe GI bleeding. - Hepatic status: check liver enzymes before initiating therapy. - Pregnancy and lactation: use only if potential benefit outweighs risk. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Meloxicam can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Lithium: elevated lithium levels. - Methotrexate: reduced clearance leading to toxicity.

Moderate Interactions (Monitor Closely): - Diuretics: possible reduction in renal perfusion. - Corticosteroids: heightened risk of GI ulceration. - SSRIs or SNRIs: modest increase in bleeding tendency. - ACE inhibitors or ARBs: potential for reduced renal function.